Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Flovent, Advair Black Box Warning Removal Sought By GSK In FDA Petition

Executive Summary

GlaxoSmithKline is asking FDA to remove the inhaled corticosteroid class "black box" warning on the grounds that physicians recognize the need to taper oral steroids before initiating therapy with inhaled products.

You may also be interested in...



GSK Advair Set To Surpass Paxil Sales With Label Change, New Indication

GlaxoSmithKline's Advair Diskus combination asthma agent is expected to surpass Paxil as the company's top-selling product within the next few years, GSK CEO J.P. Garnier told analysts in London

GSK Advair Set To Surpass Paxil Sales With Label Change, New Indication

GlaxoSmithKline's Advair Diskus combination asthma agent is expected to surpass Paxil as the company's top-selling product within the next few years, GSK CEO J.P. Garnier told analysts in London

FDA Removes Box From Inhaled Corticosteroid Adrenal Insufficiency Warning

Removal of the box surrounding the inhaled corticosteroid class warning about adrenal insufficiency in labeling is justified because no cases have been reported, FDA says

Related Content

UsernamePublicRestriction

Register

PS038067

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel